R

Roche

Global pharmaceuticals and diagnostics company

eDiscovery Specialist - Ediscovery

Full-TimeUpdated on 10/23/2026
$107.8k - $200.2k+ Discretionary annual bonus
Senior
Bachelor's
Indianapolis, IN, USA
In Person
CybersecuritySecurity Operations & Incident Response

About the job

Requirements
  • A bachelor's degree in Information Technology, Computer Science, or a related field is required.
  • At least 5 years of hands-on experience in eDiscovery, digital forensics, or specialized IT incident response is required; experience in a highly regulated global industry such as pharmaceuticals, healthcare, or finance is preferred.
  • Subject matter expert-level proficiency in Microsoft Purview, including experience designing, building, and executing legally defensible search, preservation, and collection workflows across Microsoft 365, is required.
  • Hands-on experience with Relativity and modern cloud collection environments, including Google Workspace and Slack, is required.
  • Practical experience collecting electronically stored information across Apple iOS/macOS and Windows 10/11 environments is required, including basic handling of FileVault and BitLocker encryption and remote collection methodologies.
  • Hands-on familiarity with mobile and computer collection tools such as Cellebrite UFED, Cellebrite Digital Collector, and Druva is required.
  • Experience coordinating multiple functional areas and stakeholders and managing multiple priorities and projects with accuracy and professionalism is required.
  • The role requires strong problem-solving, continuous improvement, precision, autonomy, and the ability to manage complex, time-sensitive priorities in an evolving environment.
  • The role requires the ability to translate complex technical concepts into clear explanations for legal counsel, human resources, compliance officers, and external forensic partners.
Responsibilities
  • Plan and execute legally defensible data preservation and collection strategies across the enterprise, including forensic imaging of corporate iOS, macOS, and Windows hardware, cloud-based eDiscovery using Microsoft Purview, and retrieval of case-critical data from internal systems globally.
  • Manage eDiscovery review processes and perform advanced data processing in Relativity and Purview Premium; prepare data for legal review using Boolean search strings, early case assessment, culling strategies, and technology-assisted review and artificial intelligence workflows; oversee legal productions and improve processes and technology.
  • Execute time-sensitive data requests, handle physical evidence, and collect devices across company systems; establish and maintain standard operating procedures, metrics, and audit trails for preservation, collection, and processing, maintaining chain of custody aligned with EDRM standards.
  • Oversee the operational readiness and lifecycle of Microsoft Purview, Relativity, Cellebrite, and Druva; manage software updates, troubleshoot issues, and optimize platforms for legal, compliance, and investigative needs.
  • Evaluate and refine collection workflows to account for operating-system updates and security features, including iOS, macOS, Windows 11, FileVault, BitLocker, and mobile device management profiles; deploy workflow automation and artificial intelligence improvements.
  • Develop and maintain business relationships with legal and compliance stakeholders, Roche Digital Technology, and internal and external partners; serve as a liaison to eDiscovery and internal investigations teams, translating technical concepts into clear legal realities.
Desired Qualifications
  • Experience in a highly regulated global industry such as pharmaceuticals, healthcare, or finance is preferred.
  • Relativity Certified Administrator certification is preferred.
  • Forensic certifications such as CFCE, CCE, CCME, GCFE, or GCFA are a plus but are not required.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 22nd, 2026
Roche reaffirms outlook as Q3 sales rise 7% to $19.6B, but growth doubts linger

Roche reaffirmed its 2025 outlook on Thursday and beat third-quarter sales expectations, but questions about its long-term growth remain. Group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), ahead of the 15.8 billion franc consensus estimate. Jefferies analyst Michael Leuchten said a new resource planning system boosted revenue, making the results "cosmetically ahead." Roche still expects group sales growth in the "mid single digit range" and did not raise guidance. Sales of allergy and asthma drug Xolair reached only 848 million francs, well below estimates. A copycat version launched in the US this month, and Ocrevus and Tecentriq face generic competition by 2030. Roche is counting on its breast cancer pill giredestrant, which awaits a US Food and Drug Administration decision by December 18, and on obesity drugs. It says the products could together reach $9 billion in peak annual sales.

CNBC
Oct 22nd, 2026
Roche CEO presses Germany on growth strategy as drugmaker pauses investment there

Roche chief executive officer Thomas Schinecker has challenged Germany over its growth strategy, saying pharmaceutical firms are "the industry they need to bet on." Schinecker discussed the company's third-quarter earnings and its recent expansion in China. He also outlined recent pharmaceutical developments at the business. He explained why Roche has paused investment in Germany.

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.